DrugTimes：InnoCare Pharma: A Sample of Accelerated Commercialization for Biotech Companies

OncLive：China’s NMPA Grants Priority Review to Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

PharmaBoardroom Interviews Jasmine Cui, Founder & CEO, InnoCare

Blood Advances: Orelabrutinib for the Treatment of Relapsed or Refractory MCL: A Phase 1/2, Open-label, Multicenter, Single-arm Study

China Daily: New Treatment Approved for Marginal Zone Lymphoma

American Journal of Hematology (AJH): Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 Study

Pharmaceutical Business Review: InnoCare receives approval in Singapore for mantle cell lymphoma therapy

Scrip/Pharma Intelligence: Still the Place to Do Drug Innovation': China Biotech CEO Podcast with InnoCare’s Jasmine Cui

Delaware Business Now: Inctyte, InnoCare partner on development of cancer treatment drug in Greater China

BioSpace: China’s InnoCare Pharma Raises $289 Million in IPO